Fidelity Investments
BEAM icon

Fidelity Investments’s Beam Therapeutics BEAM Stock Holding History

Fidelity Investments’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$433M Buy
12,609,002
+156,803
+1% +$4.73M 0.02% 608
2026
Q1 		$297M Buy
12,452,199
+543,061
+5% +$15.1M 0.02% 693
2025
Q4 		$330M Buy
11,909,138
+216,285
+2% +$5.52M 0.02% 664
2025
Q3 		$284M Sell
11,692,853
-1,268,606
-10% -$25.2M 0.01% 709
2025
Q2 		$220M Buy
12,961,459
+5,041,406
+64% +$87.8M 0.01% 777
2025
Q1 		$155M Buy
7,920,053
+4,602,759
+139% +$121M 0.01% 915
2024
Q4 		$82.3M Sell
3,317,294
-894,223
-21% -$22.8M ﹤0.01% 1191
2024
Q3 		$103M Sell
4,211,517
-196,178
-4% -$5.07M 0.01% 1087
2024
Q2 		$103M Sell
4,407,695
-486,758
-10% -$12M 0.01% 1027
2024
Q1 		$162M Sell
4,894,453
-1,285,869
-21% -$40.1M 0.01% 872
2023
Q4 		$168M Sell
6,180,322
-317,509
-5% -$7.89M 0.01% 817
2023
Q3 		$156M Sell
6,497,831
-639,878
-9% -$17.2M 0.01% 798
2023
Q2 		$228M Buy
7,137,709
+1,050,156
+17% +$34.1M 0.02% 671
2023
Q1 		$186M Buy
6,087,553
+1,121,564
+23% +$44.3M 0.02% 737
2022
Q4 		$194M Buy
4,965,989
+381,854
+8% +$17.1M 0.02% 696
2022
Q3 		$218M Sell
4,584,135
-215,964
-4% -$12.3M 0.02% 628
2022
Q2 		$186M Sell
4,800,099
-614,997
-11% -$24.4M 0.02% 718
2022
Q1 		$310M Buy
5,415,096
+1,493,793
+38% +$98M 0.02% 620
2021
Q4 		$312M Sell
3,921,303
-2,863
-0.1% -$245K 0.02% 629
2021
Q3 		$341M Sell
3,924,166
-3,761,094
-49% -$378M 0.03% 575
2021
Q2 		$989M Buy
7,685,260
+1
+0% +$80 0.08% 231
2021
Q1 		$615M Buy
7,685,259
+356,673
+5% +$33.9M 0.05% 361
2020
Q4 		$598M Hold
7,328,586
– – 0.05% 351
2020
Q3 		$180M Buy
7,328,586
+356,674
+5% +$8.85M 0.02% 667
2020
Q2 		$195M Hold
6,971,912
– – 0.02% 622
2020
Q1 		$125M Buy
+6,971,912
New +$152M 0.02% 678

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments's BEAM Position: Q2 2026 in Review

Fidelity Investments increased its Beam Therapeutics (BEAM) stake by 1.3% in Q2 2026, buying an estimated $4.73M and bringing the position to 12,609,002 shares worth $433M. The position accounts for 0.02% of the portfolio, ranked #608.

Fidelity Investments first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $989M in Q2 2021. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Fidelity Investments held 12,609,002 shares of Beam Therapeutics worth $433M as of Q2 2026.
  • Fidelity Investments bought 156,803 Beam Therapeutics shares in Q2 2026, an estimated $4.73M.
  • Beam Therapeutics made up 0.02% of Fidelity Investments's portfolio in Q2 2026, its #608 holding.
  • Fidelity Investments first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Fidelity Investments's Beam Therapeutics position peaked at $989M in Q2 2021.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.